Consun Pharmaceutical Group Limited (01681) released a Next Day Disclosure Return dated 05 November 2025. The total number of issued ordinary shares remained at 847,973,407 as of that date, unchanged from the opening balance.

According to the announcement, between 14 October 2025 and 05 November 2025, 3,896,000 shares were repurchased for cancellation but had not yet been cancelled as of the closing balance date. These repurchases were executed at prices ranging roughly from HKD 14.77 to HKD 15.76 per share.

On 05 November 2025, 200,000 ordinary shares were additionally repurchased on the exchange at prices between HKD 14.81 and HKD 15.00, for an aggregate consideration of HKD 2,982,260. The repurchases were conducted under the company’s existing repurchase mandate granted on 22 May 2025, which authorizes up to 85,126,334 shares to be bought back (representing approximately 10.6794% of the number of issued shares as at the date of that resolution).

The announcement also indicates that, subject to applicable rules, there is a moratorium on new share issues or sales or transfers of treasury shares until 05 December 2025 following the recent share repurchase activities.